Evidence map›Paper›PMID 37632562›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers.

Stephane Niyoteka, Romain-David Seban, Rahimeh Rouhi, Andrew Scarsbrook, Catherine Genestie, Marion Classe, Alexandre Carré, Roger Sun, Agustina La Greca Saint-Esteven, Cyrus Chargari and 9 more

Open access · greenAbstract readComment
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Diagnostics (Basel, Switzerland) · 2024
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Stephane NiyotekaUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France. stephane.niyoteka@gustaveroussy.fr.ORCID 0000-0001-6360-7086
Romain-David SebanDepartment of Nuclear Medicine, Institut Curie, Saint Cloud, France.
Rahimeh RouhiUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Andrew ScarsbrookDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Catherine GenestiePathology Department, Gustave Roussy, F-94805, Villejuif, France.
Marion ClasseUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Alexandre CarréUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Roger SunUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Agustina La Greca Saint-EstevenDepartment of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland.
Cyrus ChargariUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Jack McKennaDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Garry McDermottDepartment of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Eirik MalinenDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Stephanie Tanadini-LangDepartment of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital of Zurich, Zurich, Switzerland.
Marianne G GurenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Claire LemanskiDepartment of Radiation Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.
Eric DeutschUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Charlotte RobertUniversité Paris Saclay, INSERM UMR1030, Gustave Roussy, 94805, Villejuif, France.
Inserm · FRUniversity Hospital of Zurich · CHInstitut Gustave Roussy · FRLeeds Teaching Hospitals NHS Trust · GBOslo University Hospital · NOInstitut de Recherche en Cancérologie de Montpellier · FRUniversity of Leeds · GB

Funding

Cancer Research UK 28832
6 · The paper itself

Abstract

Locally advanced cervical cancer (LACC) and anal and oropharyngeal squamous cell carcinoma (ASCC and OPSCC) are mostly caused by oncogenic human papillomaviruses (HPV). In this paper, we developed machine learning (ML) models based on clinical, biological, and radiomic features extracted from pre-treatment fluorine-18-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET) images to predict the survival of patients with HPV-induced cancers. For this purpose, cohorts from five institutions were used: two cohorts of patients treated for LACC including 104 patients from Gustave Roussy Campus Cancer (Center 1) and 90 patients from Leeds Teaching Hospitals NHS Trust (Center 2), two datasets of patients treated for ASCC composed of 66 patients from Institut du Cancer de Montpellier (Center 3) and 67 patients from Oslo University Hospital (Center 4), and one dataset of 45 OPSCC patients from the University Hospital of Zurich (Center 5). Radiomic features were extracted from baseline [18F]-FDG PET images. The ComBat technique was applied to mitigate intra-scanner variability. A modified consensus nested cross-validation for feature selection and hyperparameter tuning was applied on four ML models to predict progression-free survival (PFS) and overall survival (OS) using harmonized imaging features and/or clinical and biological variables as inputs. Each model was trained and optimized on Center 1 and Center 3 cohorts and tested on Center 2, Center 4, and Center 5 cohorts. The radiomic-based CoxNet model achieved C-index values of 0.75 and 0.78 for PFS and 0.76, 0.74, and 0.75 for OS on the test sets. Radiomic feature-based models had superior performance compared to the bioclinical ones, and combining radiomic and bioclinical variables did not improve the performances. Metabolic tumor volume (MTV)-based models obtained lower C-index values for a majority of the tested configurations but quite equivalent performance in terms of time-dependent AUCs (td-AUC). The results demonstrate the possibility of identifying common PET-based image signatures for predicting the response of patients with induced HPV pathology, validated on multi-center multiconstructor data.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellPapillomavirus InfectionsUterine Cervical NeoplasmsFemaleFluorine RadioisotopesFluorodeoxyglucose F18Human Papillomavirus VirusesHumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyRetrospective StudiesFluorine-18Fluorine RadioisotopesFluorodeoxyglucose F18[18F]-FDG PETASCCComBatHumano papillomavirusLACCOPSCCRadiomics

Identifiers

PMID37632562
OpenAlexW4386195508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.